David Pelizzon Sells 4,000 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 4,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00. Following the completion of the sale, the director owned 6,897,764 shares of the company’s stock, valued at approximately $177,617,423. The trade was a 0.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OrthoPediatrics Stock Performance

Shares of KIDS stock traded down $0.47 during trading hours on Wednesday, reaching $24.03. 169,608 shares of the company’s stock were exchanged, compared to its average volume of 171,545. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company’s 50 day moving average is $21.11 and its two-hundred day moving average is $18.53. The company has a market cap of $627.42 million, a P/E ratio of -14.30 and a beta of 0.98. OrthoPediatrics Corp. has a 1 year low of $14.42 and a 1 year high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Equities research analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after acquiring an additional 645 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares during the last quarter. BNP Paribas Financial Markets increased its position in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares in the last quarter. Legal & General Group Plc purchased a new stake in OrthoPediatrics during the 2nd quarter worth about $34,000. Finally, Northwestern Mutual Wealth Management Co. raised its stake in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research boosted their price target on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Finally, Needham & Company LLC boosted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, OrthoPediatrics presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.